Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL469 (Ketorolac, Ketorolaco) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
aldo-keto reductase family 1 member B/Aldose reductase in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2622] [GtoPdb: 2768] [UniProtKB: P07943] | ||||||||
ChEMBL | DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) | B | 5.21 | pIC50 | 6109 | nM | IC50 | DrugMatrix in vitro pharmacology data |
COX-1 /Cyclooxygenase-1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL221] [GtoPdb: 1375] [UniProtKB: P23219] | ||||||||
GtoPdb | Instantaneous inhibition of human COX1 by compound (no pre-incubation). | - | 4.5 | pIC50 | 31500 | nM | IC50 | J Med Chem (2011) 54: 8555-62 [PMID:22091869] |
ChEMBL | Inhibition of human COX1 | B | 5.91 | pIC50 | 1230 | nM | IC50 | Eur J Med Chem (2016) 114: 257-292 [PMID:26994693] |
ChEMBL | DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) | B | 7.89 | pIC50 | 13 | nM | IC50 | DrugMatrix in vitro pharmacology data |
GtoPdb | - | - | 9.72 | pIC50 | 0.19 | nM | IC50 | Proc Natl Acad Sci USA (1999) 96: 7563-8 [PMID:10377455] |
COX-2 /Cyclooxygenase-2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL230] [GtoPdb: 1376] [UniProtKB: P35354] | ||||||||
GtoPdb | Instantaneous inhibition of human COX2 by compound (no pre-incubation). | - | 4.22 | pIC50 | 60500 | nM | IC50 | J Med Chem (2011) 54: 8555-62 [PMID:22091869] |
ChEMBL | Inhibition of human COX2 | B | 5.46 | pIC50 | 3500 | nM | IC50 | Eur J Med Chem (2016) 114: 257-292 [PMID:26994693] |
ChEMBL | DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) | B | 6.37 | pIC50 | 424 | nM | IC50 | DrugMatrix in vitro pharmacology data |
ChEMBL | Inhibition of recombinant human COX2 using arachidonic acid as substrate measured after 2 to 5 mins | B | 6.85 | pIC50 | 140 | nM | IC50 | Eur J Med Chem (2017) 126: 270-276 [PMID:27889630] |
GtoPdb | Inhibition of human COX2 measured after pre-incubation of enzyme with compound. | - | 6.92 | pIC50 | 120 | nM | IC50 | J Med Chem (2011) 54: 8555-62 [PMID:22091869] |
fatty acid binding protein 1/Fatty acid-binding protein, liver in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5738] [GtoPdb: 2531] [UniProtKB: P02692] | ||||||||
ChEMBL | Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay | B | 4.94 | pKi | 11600 | nM | Ki | J Med Chem (2008) 51: 3755-3764 [PMID:18533710] |
L-PGDS/Prostaglandin-H2 D-isomerase in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4334] [GtoPdb: 1380] [UniProtKB: O09114] | ||||||||
ChEMBL | Concentration required to inhibit 50% activity of prostaglandin synthetase was determined in vitro in mouse brain microsomes | B | 6.64 | pIC50 | 230 | nM | IC50 | J Med Chem (1991) 34: 1099-1110 [PMID:1900533] |
p21 (RAC1) activated kinase 1/Serine/threonine-protein kinase PAK 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4600] [GtoPdb: 2133] [UniProtKB: Q13153] | ||||||||
ChEMBL | Inhibition of PAK1 in human A549 cells using myelin basic protein as substrate preincubated for 24 hrs followed by PAK1 immunoprecipation and substrate addition measured after 60 mins by ATP-Glo kinase assay | B | 4.44 | pIC50 | 36000 | nM | IC50 | Eur J Med Chem (2017) 126: 270-276 [PMID:27889630] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]